不同双联抗栓方案治疗下肢动脉硬化闭塞症疗效及安全性

Efficacy and Safety of Different Dual Antithrombotic Therapies in Patients with Lower Extremity Arteriosclerosis Obliterans

目的探讨不同抗血小板药物联合利伐沙班对下肢动脉硬化闭塞症患者的疗效及安全性。方法回顾性分析2018年1月—2021年12月南京鼓楼医院血管外科收治的有症状并接受手术治疗的下肢动脉硬化闭塞症患者的临床资料,根据患者服用抗血小板药物的种类,分为阿司匹林组、氯吡格雷组以及西洛他唑组,收集患者基线资料,对患者进行随访,比较不同组患者严重不良心血管事件、严重不良肢体事件以及出血事件的发生率。结果共纳入患者632例,采用逆概率加权法平衡不同组间的基线数据后不同组之间严重不良心血管事件、严重不良肢体事件、大出血以及临床相关非大出血事件的发生率均差异无统计学意义,亚组分析的结果基本与总体研究结果一致。结论氯吡格雷和西洛他唑分别与利伐沙班联用能够成为下肢动脉硬化闭塞症患者双联抗栓治疗方案的新选择。

Objective To explore the efficacy and safety of different antiplatelet drugs combined with rivaroxaban in patients with lower extremity arteriosclerosis obliterans.Methods The clinical data of patients with lower extremity arteriosclerosis obliterans who were symptomatic and underwent surgical treatment at the Vascular Surgery Department of Nanjing Drum Tower Hospital from January 2018 to December 2021 were retrospectively analyzed.According to the different antiplatelet medications taken by patients,patients were categorized into aspirin group,clopidogrel group and cilostazol group.Baseline data of patients were collected,and patients were followed up and the incidence of major adverse cardiovascular events,major adverse limb events,major bleeding and clinically related non-major bleeding events were compared in different groups.Results A total of 632 patients were included in the study.There was no significant difference in the incidence of major adverse cardiovascular events,major adverse limb events,major bleeding and clinically related non-major bleeding events after the baseline data was balanced by inverse probability of treatment weighting.The results of subgroup analysis were generally consistent with those of the overall study.Conclusion The combination of clopidogrel or cilostazol with rivaroxaban may serve as a novel option for dual antithrombotic therapy in patients diagnosed with lower extremity arteriosclerotic obliterans.